AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 33621109
Drug: Lenalidomide oral
RxNorm normalized name: lenalidomide Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenalidomide oral 15 mg/d, days 1‐14/21 plus standard R‐CHOP21
Trial: 32192317
Drug: Pharmacological therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacological therapy alone
Trial: 35346499
Drug: Aspirin-Cinnamon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin-Cinnamon
Trial: 33651438
Drug: GLP‐1RA exenatide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLP‐1RA exenatide once‐weekly (ExQW) for 36 weeks
Trial: 33436031
Drug: Clear presentation
RxNorm normalized name: Caladryl Clear
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Clear presentation of medical and surgical treatment options.
Trial: 34756787
Drug: Roxadustat treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roxadustat treatment for 12 weeks
Trial: 33158422
Drug: Standard healthy
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard healthy life prescription (PVS)
Trial: 34293955
Drug: Active phase
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active phase with smart insulin pen cap (alarms/reminders)
Trial: 35236652
Drug: Chemotherapy (Control)
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (Control)
Trial: 32737670
Drug: Mindfulness-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-based treatment targeting emotion regulation problems over 16 weeks
Trial: 32394851
Drug: Perindopril, indapamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril, indapamide SR, and metformin (n=40)
Trial: 32394851
Drug: Perindopril, moxonidin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril, moxonidin, and metformin (n=40)
Trial: 35343796
Drug: Probiotic group
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic group (Bifidobacterium lactis Probio-M8, atorvastatin, metoprolol)
Trial: 35343796
Drug: Placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group (placebo, atorvastatin, metoprolol)
Trial: 35228291
Drug: Prophylactic anticoagulation
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic anticoagulation (rivaroxaban 10 mg once a day for 3 months)
Trial: 35228291
Drug: Therapeutic anticoagulation
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic anticoagulation (rivaroxaban 20 mg once a day for 3 months)
Trial: 33839979
Drug: Postoperative Adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative Adjuvant Transarterial Infusion Chemotherapy with FOLFOX
Trial: 33792511
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (waiting for treatment)
Trial: 34719399
Drug: Magnesium oxide
RxNorm normalized name: Magnesium Oxide
DrugBank: Magnesium oxide (DB01377)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Magnesium oxide monohydrate (MOMH) 226 mg, once daily at bedtime for 60 days
Trial: 34719399
Drug: Placebo, once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, once daily at bedtime for 60 days
Trial: 35020101
Drug: Topical nalbuphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical nalbuphine 2 mg/ml (Group A)
Trial: 35020101
Drug: Topical nalbuphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical nalbuphine 1 mg/ml (Group B)
Trial: 35020101
Drug: Topical artificial
RxNorm normalized name: COLOR,ARTIFICIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical artificial tears (Group C)
Trial: 34933333
Drug: Azacitidine 75
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azacitidine 75 mg/m2 on days 1 through 7 with durvalumab 1500 mg on day 1 every 4 weeks (Arm A)
Trial: 34933333
Drug: Azacitidine 75
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azacitidine 75 mg/m2 on days 1 through 7 without durvalumab (Arm B)
Trial: 33729467
Drug: nCT (neoadjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nCT (neoadjuvant chemotherapy) followed by minimally invasive esophagectomy (MIE)
Trial: 33515267
Drug: Non-nicotinic e-cigarettes
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Non-nicotinic e-cigarettes with 4 mg nicotine lozenge (ENL)
Trial: 33515267
Drug: Non-nicotinic e-cigarettes
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Non-nicotinic e-cigarettes with placebo lozenges (EPL)
Trial: 32769965
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care chemotherapy (SC)
Trial: 34981580
Drug: Red Light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red Light (RL) therapy
Trial: 34981580
Drug: Blue Light
RxNorm normalized name: Ocuvite Blue Light Mini Softgel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blue Light (BL) therapy
Trial: 35121105
Drug: Subcutaneous immunoglobulin
RxNorm normalized name: immunoglobulin A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous immunoglobulin Gammanorm® via pump
Trial: 35121105
Drug: Subcutaneous immunoglobulin
RxNorm normalized name: immunoglobulin A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous immunoglobulin Gammanorm® via rapid push
Trial: 35121105
Drug: Subcutaneous immunoglobulin
RxNorm normalized name: immunoglobulin A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous immunoglobulin Gammanorm® via pump and rapid push
Trial: 33773207
Drug: Metformin (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (1000 mg) with methotrexate (7.5 mg/week)
Trial: 33773207
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with methotrexate (7.5 mg/week)
Trial: 33389108
Drug: TAU (Treatment-As-Usual)
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAU (Treatment-As-Usual)
Trial: 32022483
Drug: Mometasone furoate-formoterol
RxNorm normalized name: mometasone
DrugBank: Mometasone (DB00764)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mometasone furoate-formoterol (MF/F) 100/10 µg
Trial: 32022483
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate (MF) 100 µg
Trial: 35583988
Drug: Group logotherapy
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group logotherapy (10 weekly 2-hour sessions)
Trial: 32777998
Drug: L-theanine 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-theanine 400 mg
Trial: 36263942
Drug: L-theanine 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-theanine 100 mg
Trial: 36263942
Drug: L-theanine 200
RxNorm normalized name: L-theanine 200 MG Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-theanine 200 mg
Trial: 34816597
Drug: Hybrid closed-loop
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hybrid closed-loop (HCL) insulin delivery 24/7
Trial: 34816597
Drug: Evening and
RxNorm normalized name: Evenity
DrugBank: Romosozumab (DB11866)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Evening and night (E/N) hybrid closed-loop insulin delivery
Trial: 34805194
Drug: Open-label placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-label placebo injections (two per day on day 1 and 2 post-surgery) along with treatment as usual (patient-controlled morphine pump)
Trial: 34805194
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (patient-controlled morphine pump)
Trial: 34805194
Drug: Open-label placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-label placebo injections
Trial: 35618537
Drug: Advanced regional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Advanced regional analgesic techniques
Trial: 35618537
Drug: Basic analgesics
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic analgesics (paracetamol, NSAIDs, cyclooxygenase-2 inhibitors, dexamethasone, local infiltration analgesia)
Trial: 32938572
Drug: Self-administered questionnaire
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-administered questionnaire assessing knowledge, attitude, and practice regarding emergency management of TDI.
Trial: 32938572
Drug: Self-administered questionnaire
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-administered questionnaire assessing perceived knowledge level.
Trial: 32248707
Drug: Polynucleotide (PN)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polynucleotide (PN) filler injection
Trial: 32248707
Drug: Non-crosslinked hyaluronic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-crosslinked hyaluronic acid (HA) filler injection
Trial: 35807110
Drug: Bilateral QLBs-LSAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral QLBs-LSAL with 0.375% ropivacaine (20 mL each side)
Trial: 39259241
Drug: Control Condition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control Condition (CC)
Trial: 35240291
Drug: Resveratrol 200
RxNorm normalized name: resveratrol 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resveratrol 200 mg once daily for 24 weeks
Trial: 35240291
Drug: Placebo (cellulose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (cellulose capsules)
Trial: 35867532
Drug: Adjuvant hypnotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant hypnotherapy plus conventional therapy
Trial: 35279171
Drug: Anaemia screening
RxNorm normalized name: SUN PROTECTANTS/SCREENS,TOPICAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anaemia screening and treatment (anaemia arm)
Trial: 33087250
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose oral vitamin D3 (540,000 IU)
Trial: 35656394
Drug: Beta-blocker treatment
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blocker treatment
Trial: 33122344
Drug: 2 ×
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 × N-AVD (doxorubicin, vinblastine, dacarbazine with two concomitant nivolumab infusions per cycle)
Trial: 33153707
Drug: Topical mitomycin
RxNorm normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical mitomycin C
Trial: 32301501
Drug: GSK2982772, 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2982772, 60 mg twice daily (b.i.d.)
Trial: 32301501
Drug: GSK2982772, 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2982772, 60 mg three times daily (t.i.d.)
Trial: 34320288
Drug: CMV hyperimmune
RxNorm normalized name: CMV-immune globulin
DrugBank: Human cytomegalovirus immune globulin (DB13886)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMV hyperimmune globulin (100 mg/kg monthly until delivery)
Trial: 32528568
Drug: Enoxaparin-warfarin
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin-warfarin
Trial: 34024233
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (TXA) 10 mg/kg infusion in 100 mL normal saline
Trial: 34024233
Drug: Placebo (distilled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (distilled water in 100 mL normal saline)
Trial: 33099848
Drug: IDegAsp (twice-daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IDegAsp (twice-daily single injection)
Trial: 33099848
Drug: IDeg +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IDeg + Lira (once-daily dual injection)
Trial: 32521096
Drug: Concurrent Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure (COPE)
Trial: 32246743
Drug: Rivaroxaban (bodyweight-adjusted,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban (bodyweight-adjusted, administered once-daily, twice-daily, or thrice-daily)
Trial: 32246743
Drug: Rivaroxaban (tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban (tablet and suspension formulation)
Trial: 36200921
Drug: HA-filler serum
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HA-filler serum (applied starting 24 hours after BoNTA injection, then twice daily for 24 weeks)
Trial: 34857525
Drug: Danazol 800
RxNorm normalized name: Danazol
DrugBank: Danazol (DB01406)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Danazol 800 mg daily in two divided doses for adults or 2 mg/kg/day for children, escalating to 4 mg/kg/day if no side effects are encountered, for a total of 12 months for adults and 6 months for children.
Trial: 33293274
Drug: LDL-C concentrations
RxNorm normalized name: PROTEIN C CONCENTRATE
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDL-C concentrations <1.8 mmol/L (<70 mg/dL; 1st-5th centiles)
Trial: 33293274
Drug: LDL-C concentrations
RxNorm normalized name: PROTEIN C CONCENTRATE
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDL-C concentrations >4.8 mmol/L (>189 mg/dL; 96th-100th centiles)
Trial: 33293274
Drug: LDL-C concentration
RxNorm normalized name: PROTEIN C CONCENTRATE
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDL-C concentration of 3.6 mmol/L (140 mg/dL)
Trial: 33293274
Drug: LDL-C concentration
RxNorm normalized name: PROTEIN C CONCENTRATE
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDL-C concentration of 2.3 mmol/L (89 mg/dL)
Trial: 32905611
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (TXA) - bolus dose of 10 mg kg−1 followed by 8 hours continuous infusion of 3 mg kg−1 h−1
Trial: 34775948
Drug: Conventional oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional oxygen therapy (COT)
Trial: 33180007
Drug: Acute beetroot
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute beetroot juice supplementation (70 mL, 6.4 mmol NO3‐)
Trial: 32808409
Drug: Active soft
RxNorm normalized name: Nature's Way Petadolex Pro-Active Softgels
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active soft tissue therapy (stretching exercise + active soft tissue therapy)
Trial: 35086112
Drug: 0.35% levobupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.35% levobupivacaine (7 mL/h for 48 hours)
Trial: 34601736
Drug: IV ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV ibuprofen 800 mg
Trial: 34601736
Drug: IV ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV ibuprofen 800 mg and Placebo
Trial: 36100943
Drug: Virtual reality
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virtual reality therapy (7 sessions within 12 weeks)
Trial: 34202578
Drug: 5000 IU
RxNorm normalized name: D 5000 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5000 IU oral vitamin D3
Trial: 34202578
Drug: 1000 IU
RxNorm normalized name: D 1000 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 IU oral vitamin D3 (standard control)
Trial: 35239819
Drug: Medication reconciliation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication reconciliation (MED)
Trial: 33990145
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (CON)
Trial: 35910820
Drug: High-dose oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose oral ivermectin plus zinc sulfate for 3 days
Trial: 33376119
Drug: Experimental calculus
RxNorm normalized name: Anamirta cocculus fruit extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental calculus disruption solution (EXP‐955)
Trial: 36748363
Drug: CT-P17 (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT-P17 (40 mg/0.4 ml)
Trial: 36748363
Drug: EU-adalimumab (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EU-adalimumab (40 mg)
Trial: 33855449
Drug: Fosfomycin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosfomycin (100 mg/kg IV q12h for 48h, then converted to oral therapy at the same dose)
Trial: 33989086
Drug: Home medication
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Home medication review by community pharmacists (HMR-CP)
Trial: 36216274
Drug: Daily Partial
RxNorm normalized name: rosin partially dimerized glycerol ester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily Partial Breast Irradiation (PBI) - 35 Gy in 10 daily fractions, with a 9 Gy boost in 3 fractions for patients with close margins
Trial: 36216274
Drug: Daily Partial
RxNorm normalized name: rosin partially dimerized glycerol ester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily Partial Breast Irradiation (PBI)
Trial: 32700191
Drug: Single intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravenous infusions of felbinac trometamol (11.78–377.00 mg)
Trial: 32700191
Drug: Multiple intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple intravenous infusions of felbinac trometamol (47.13–188.50 mg)
Trial: 32700191
Drug: Felbinac trometamol
RxNorm normalized name: felbinac
DrugBank: Felbinac (DB07477)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felbinac trometamol (various doses)
Trial: 35500171
Drug: Aspirin with
RxNorm normalized name: Bayer Aspirin with Calcium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin with PPIs
Trial: 35500171
Drug: Aspirin without
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin without PPIs
Trial: 34214585
Drug: Montelukast 10
RxNorm normalized name: montelukast 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast 10 mg tablets once daily for 12 weeks
Trial: 34214585
Drug: Placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets once daily for 12 weeks
Trial: 34416879
Drug: Metformin (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (1000 mg daily for six months)
Trial: 33028425
Drug: Targeted normothermia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted normothermia and active treatment of fever (≥ 37.8 °C)
Trial: 36059956
Drug: Prophylactic TXA
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic TXA (10 mg/kg followed by 5 mg/kg/h) with TEG‐guided hemostatic algorithm
Trial: 32817692
Drug: Tsima intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tsima intervention (HIV treatment as prevention)
Trial: 32060155
Drug: Dexamethasone-based elixir
RxNorm normalized name: Dexamethasone Elixir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone-based elixir mouthwash (10 mL 0.1 mg/mL; swish for 2 min and spit, four times daily for 9 weeks)
Trial: 32060155
Drug: Dexamethasone-based elixir
RxNorm normalized name: Dexamethasone Elixir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone-based elixir mouthwash
Trial: 36506010
Drug: NAC treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NAC treatment of SLA-stimulated PBMCs
Trial: 32474302
Drug: Conventional lipid-lowering
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional lipid-lowering therapy (pitavastatin monotherapy)
Trial: 32474302
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (Group 3, HDL-C ≥53.6 mg/dL)
Trial: 32474302
Drug: Pitavastatin +
RxNorm normalized name: Pitavastatin
DrugBank: Pitavastatin (DB08860)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pitavastatin + ezetimibe therapy
Trial: 36908150
Drug: Pitavastatin monotherapy
RxNorm normalized name: Pitavastatin
DrugBank: Pitavastatin (DB08860)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pitavastatin monotherapy
Trial: 33339359
Drug: Caffeine-containing energy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine-containing energy shot (CAF, 5 mg/kg)
Trial: 32721973
Drug: Diuretic efficiency
RxNorm normalized name: hydralazine hydrochloride / hydrochlorothiazide / reserpine Oral Tablet [Diuretic Ap-Es]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretic efficiency
Trial: 36433919
Drug: Intensive SBP
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive SBP treatment (target 110 to <130 mmHg)
Trial: 36433919
Drug: Standard SBP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard SBP treatment (target 130 to <150 mmHg)
Trial: 39016010
Drug: Standard SBP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard SBP treatment
Trial: 33225631
Drug: Anifrolumab 1000
RxNorm normalized name: ANIFROLUMAB
DrugBank: Anifrolumab (DB11976)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anifrolumab 1000 mg IV every 4 weeks, reduced to 300 mg every 4 weeks based on benefit/risk profile